Publications (original articles or review articles) published in 2018 from OUS - Section for urological oncology
9 publications found
Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial
Eur Urol, 73 (6), 870-876
DOI 10.1016/j.eururo.2018.01.012, PubMed 29395502
Patient-reported outcomes after treatment for clinically localized prostate cancer: A systematic review and meta-analysis
Cancer Treat Rev, 66, 23-44
DOI 10.1016/j.ctrv.2018.03.005, PubMed 29673922
Local failure is a dominant mode of recurrence in locally advanced and clinical node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy
Urol Oncol, 37 (4), 289.e19-289.e26
DOI 10.1016/j.urolonc.2018.09.016, PubMed 30446451
Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer
JAMA, 319 (9), 896-905
DOI 10.1001/jama.2018.0587, PubMed 29509865
Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study
Int J Radiat Oncol Biol Phys, 101 (4), 883-888
DOI 10.1016/j.ijrobp.2018.03.060, PubMed 29976500
SPCG-15: a prospective randomized study comparing primary radical prostatectomy and primary radiotherapy plus androgen deprivation therapy for locally advanced prostate cancer
Scand J Urol, 52 (5-6), 313-320
DOI 10.1080/21681805.2018.1520295, PubMed 30585526
Localization of radio-recurrence within the prostate: anti-3-18F-FACBC PET/CT compared with multiparametric MRI using histopathology as reference standard
Acta Radiol, 60 (8), 1028-1038
DOI 10.1177/0284185118810977, PubMed 30379559
Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort
Radiother Oncol, 132, 211-217
DOI 10.1016/j.radonc.2018.10.013, PubMed 30389241
Weekly versus 3-weekly cabazitaxel for the treatment of castration-resistant prostate cancer: A randomised phase II trial (ConCab)
Eur J Cancer, 97, 33-40
DOI 10.1016/j.ejca.2018.03.007, PubMed 29685343